Tilivapram Transdermal Delivery for Neuropsychiatric Cognitive Deficits

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a continuing need for improved treatments for neuropsychiatric disorders such as schizophrenia and Parkinson's disease, as existing treatments may not adequately address cognitive impairments, memory issues, and processing speed deficits.

Innovation Solution

The administration of tilivapram, zatolmilast, roflumilast, or their pharmaceutically acceptable salts, either orally or transdermally, alone or in combination with antipsychotic agents, to treat neuropsychiatric disorders, including schizophrenia and Parkinson's disease, thereby improving cognitive function and addressing specific symptoms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing treatments are used for neuropsychiatric disorders, then some symptoms may be managed, but cognitive impairments, memory issues, and processing speed deficits are not adequately addressed

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidability to address cognitive impairments

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent combines PDE4 inhibition (tilivapram, zatolmilast, or roflumilast) with antipsychotic agents to create a synergistic treatment approach that addresses both positive symptoms and cognitive impairments in neuropsychiatric disorders, thereby improving overall treatment effectiveness and versatility

Inventive Principle:

Principle #5Merging (Combining)

2Reliability

If PDE4 inhibitors are administered to improve cognitive function, then pro-cognitive effects are achieved, but gastrointestinal side effects may occur

Engineering Contradiction:

Improvecognitive improvementVSAvoidgastrointestinal side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent utilizes transdermal delivery to change the administration parameter from oral to topical, providing sustained release of PDE4 inhibitors that maintains therapeutic blood levels while reducing gastrointestinal side effects associated with oral administration

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250120957A1Treatment of neuropsychiatric disorders with tilivapram

Publication Date: 2025.04.17 ALTO NEUROSCIENCE INC

AI summary

This invention relates to the treatment of a neuropsychiatric disorder, such as schizophrenia or Parkinson's disease, by administration (for example, transdermally) of tilivapram, zatolmilast, roflumilast, or a pharmaceutically acceptable salt thereof.